|
|
|
Volumn , Issue 77, 2005, Pages 1-4
|
|
Atrasentan for metastatic hormone refractory prostate cancer.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ENDOTHELIN 1;
ENDOTHELIN RECEPTOR;
PYRROLIDINE DERIVATIVE;
ARTICLE;
BONE TUMOR;
CANADA;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DRUG ANTAGONISM;
DRUG APPROVAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
MALE;
METASTASIS;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PHYSIOLOGY;
PROSTATE TUMOR;
RANDOMIZED CONTROLLED TRIAL;
SURVIVAL RATE;
TREATMENT OUTCOME;
UNITED STATES;
BONE NEOPLASMS;
CANADA;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE III;
DRUG APPROVAL;
ENDOTHELIN-1;
HUMANS;
MALE;
NEOPLASM METASTASIS;
PROSTATIC NEOPLASMS;
PYRROLIDINES;
RANDOMIZED CONTROLLED TRIALS;
RECEPTORS, ENDOTHELIN;
SURVIVAL RATE;
TREATMENT OUTCOME;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 33645116422
PISSN: 14886324
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|
